Statements (31)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
gptkb:monoclonal_antibody |
| gptkbp:activeIngredient |
gptkb:tisotumab_vedotin
|
| gptkbp:approvalYear |
2021-09-20
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
L01FX20
|
| gptkbp:form |
solution for infusion
|
| gptkbp:genericName |
gptkb:tisotumab_vedotin
|
| https://www.w3.org/2000/01/rdf-schema#label |
Tivdak
|
| gptkbp:indication |
treatment of recurrent or metastatic cervical cancer
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Genmab
gptkb:Seagen_Inc. |
| gptkbp:mechanismOfAction |
tissue factor-directed antibody and microtubule inhibitor conjugate
|
| gptkbp:pregnancyCategory |
not recommended
|
| gptkbp:prescriptionRequired |
https://www.tivdak.com/
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
nausea
fatigue alopecia conjunctivitis peripheral neuropathy thrombocytopenia ocular toxicity hemorrhage epistaxis dry eye keratitis |
| gptkbp:target |
tissue factor
|
| gptkbp:bfsParent |
gptkb:Seagen
|
| gptkbp:bfsLayer |
5
|